248 related articles for article (PubMed ID: 17192488)
1. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.
Kobayashi M; Ikegami H; Fujisawa T; Nojima K; Kawabata Y; Noso S; Babaya N; Itoi-Babaya M; Yamaji K; Hiromine Y; Shibata M; Ogihara T
Diabetes; 2007 Jan; 56(1):239-47. PubMed ID: 17192488
[TBL] [Abstract][Full Text] [Related]
2. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation.
Brinton EA
Diabetes Obes Metab; 2008 Nov; 10(11):1004-11. PubMed ID: 18494807
[TBL] [Abstract][Full Text] [Related]
3. Colestimide improves glycemic control via hepatic glucose production in db/db mice.
Yamakawa T; Ogihara K; Utsunomiya H; Muraoka T; Kadonosono K; Terauchi Y
Endocr J; 2014; 61(5):425-36. PubMed ID: 24553582
[TBL] [Abstract][Full Text] [Related]
4. Effects of colestimide and/or Bofu-tsusho-san on plasma and liver lipids in mice fed a high-fat diet.
Sakamoto S; Takeshita S; Sassa S; Suzuki S; Ishikawa Y; Kudo H
In Vivo; 2005; 19(6):1029-33. PubMed ID: 16277017
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.
Takebayashi K; Suetsugu M; Matsumoto S; Aso Y; Inukai T
South Med J; 2009 Apr; 102(4):361-8. PubMed ID: 19279518
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced effects on cholesterol catabolism and bile acids.
Gylling H; Miettinen TA
Curr Opin Investig Drugs; 2006 Mar; 7(3):214-8. PubMed ID: 16555681
[TBL] [Abstract][Full Text] [Related]
7. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study.
Suzuki T; Oba K; Igari Y; Watanabe K; Matsumura N; Futami-Suda S; Ouchi M; Suzuki K; Sekimizu K; Kigawa Y; Nakano H
J Diabetes Complications; 2012; 26(1):34-9. PubMed ID: 22240263
[TBL] [Abstract][Full Text] [Related]
8. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.
Yamakawa T; Takano T; Utsunomiya H; Kadonosono K; Okamura A
Endocr J; 2007 Feb; 54(1):53-8. PubMed ID: 17102570
[TBL] [Abstract][Full Text] [Related]
9. Diazoxide prevents abdominal adiposity and fatty liver in obese OLETF rats at prediabetic stage.
Guo Z; Bu S; Yu Y; Ghatnekar G; Wang M; Chen L; Bu M; Yang L; Zhu B; Feng Z; Huang Q
J Diabetes Complications; 2008; 22(1):46-55. PubMed ID: 18191077
[TBL] [Abstract][Full Text] [Related]
10. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
11. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
Reasner CA
J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic effects of colestimide on type 2 diabetic patients with obesity.
Neda T; Inukai K; Kurihara S; Ono H; Hosaka T; Nakamoto H; Katayama S; Awata T
Endocr J; 2012; 59(3):239-46. PubMed ID: 22230809
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance at the crossroads of metabolic syndrome: systemic analysis using microarrays.
Kim E
Biotechnol J; 2010 Sep; 5(9):919-29. PubMed ID: 20669253
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
16. Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives.
Rossmeisl M; Jelenik T; Jilkova Z; Slamova K; Kus V; Hensler M; Medrikova D; Povysil C; Flachs P; Mohamed-Ali V; Bryhn M; Berge K; Holmeide AK; Kopecky J
Obesity (Silver Spring); 2009 May; 17(5):1023-31. PubMed ID: 19148125
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome.
Kato T; Inagaki K; Sawai Y; Kanayama H; Katada N; Itoh M
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):554-8. PubMed ID: 21472664
[TBL] [Abstract][Full Text] [Related]
18. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
[TBL] [Abstract][Full Text] [Related]
19. Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose.
Rave K; Roggen K; Dellweg S; Heise T; tom Dieck H
Br J Nutr; 2007 Nov; 98(5):929-36. PubMed ID: 17562226
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
